Literature DB >> 33334700

Guidelines of the French Society of Otorhinolaryngology (SFORL) for teleconsultation in patients with vertigo during the COVID-19 pandemic.

P Bertholon1, H Thai-Van2, D Bouccara3, M-J Esteve-Fraysse4, S R Wiener-Vacher5, E Ionescu6.   

Abstract

OBJECTIVES: In the context of the SARS-CoV-2 pandemic, patients may have been dissuaded from seeking consultation, thus exposing themselves to a risk of loss of chance. This guide aims to define how teleconsultation can assist in assessing vertiginous adults or children, and to gather the information needed to provide quick medical care.
METHODS: These recommendations rely on the authors' experience as well as on literature. A survey on otoneurologic approach via telemedicine has been conducted based on a literature search until March 2020.
RESULTS: The first clinical assessment of the vertiginous patient via teleconsultation can only be successful if the following conditions are met: initial contact to verify the feasibility of the assessment at a distance, the presence of a caregiver in order to assist the patient, the possibility of making video recordings. Medical history via telemedicine, as in a face-to-face assessment, allows to assess the characteristics, duration, frequency, and potential triggering factors of the vertigo, in both children and adults. During teleconsultation, the following tests can be carried out: oculomotricity evaluation, assessment of balance, simple neurological tests, checking for positional vertigo/nystagmus and, eventually to perform canalith-repositioning procedures. In children, the following should be searched for: history of hearing or visual impairment, a context of fever or trauma, otorrhea, signs of meningeal irritation.
CONCLUSION: The neurotologic telemedicine relies on the accuracy of the clinical assessment, which is based on history taking and a few simple tests, encouraging the development of a decision-making algorithm adapted for teleconsultation. However, the latter has its limitations during an emergency examination of a new patient presenting vertigo, and, at least in some cases, cannot replace a face-to-face consultation. Teleconsultation is often adapted for follow-up consultations of previously selected vertiginous patients during face-to-face assessment.
Copyright © 2020. Published by Elsevier Masson SAS.

Entities:  

Keywords:  COVID-19; Coronavirus; Epley manoeuvre; Neurotology; Pandemic; SARS-CoV-2; Teleconsultation; Telemedicine; Vertigo

Year:  2020        PMID: 33334700     DOI: 10.1016/j.anorl.2020.11.011

Source DB:  PubMed          Journal:  Eur Ann Otorhinolaryngol Head Neck Dis        ISSN: 1879-7296            Impact factor:   2.080


  5 in total

Review 1.  Telemedicine in Audiology. Best practice recommendations from the French Society of Audiology (SFA) and the French Society of Otorhinolaryngology-Head and Neck Surgery (SFORL).

Authors:  H Thai-Van; D Bakhos; D Bouccara; N Loundon; M Marx; T Mom; I Mosnier; S Roman; C Villerabel; C Vincent; F Venail
Journal:  Eur Ann Otorhinolaryngol Head Neck Dis       Date:  2020-10-21       Impact factor: 2.665

2.  COVID-19 and the resurgence of telehealth in otolaryngology.

Authors:  Christina H Fang; Richard V Smith
Journal:  Oper Tech Otolayngol Head Neck Surg       Date:  2022-04-28

3.  Answer to the Letter to the Editor: Smartphone, Vestibular Hypofunction, Teleconsultation, and COVID-19 Pandemic.

Authors:  Renato Gonzaga Barreto; Darío Andrés Yacovino; Marcello Cherchi; Saulo Nardy Nader; Lázaro Juliano Teixeira; Delice Alves da Silva; Daniel Hector Verdecchia
Journal:  Int Arch Otorhinolaryngol       Date:  2022-05-20

4.  The Spectrum of Vestibular Disorders Presenting With Acute Continuous Vertigo.

Authors:  Qingxiu Yao; Zhuangzhuang Li; Maoxiang Xu; Yumeng Jiang; Jingjing Wang; Hui Wang; Dongzhen Yu; Shankai Yin
Journal:  Front Neurosci       Date:  2022-07-13       Impact factor: 5.152

Review 5.  New Frontiers in Managing the Dizzy Patient.

Authors:  Desi P Schoo; Bryan K Ward
Journal:  Otolaryngol Clin North Am       Date:  2021-07-20       Impact factor: 1.866

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.